Scholarlink

<p>Bipolar depression (BD-D) is a significant clinical challenge associated with high disease burden. Transcranial temporal interference stimulation (tTIS), a novel and noninvasive approach for targeting deep brain structures, was investigated for its efficacy and safety in BD-D patients in this trial. Thirty-six patients were recruited for a single-arm, open-label trial, and 25 completed the 5-day intervention consisting of 10 tTIS sessions targeting the left nucleus accumbens. Each session lasted 20 min, with a maximum current intensity of 2 mA and an envelope stimulation frequency of 40 Hz. Significant symptom reductions were observed following treatment, with mean HAMD-17 scores&#xa0;decreasing from 23.36 to&#xa0;16.16 (<i>p</i> &lt; 0.0001), MADRS scores&#xa0;from 39.12&#xa0;to&#xa0;31.28 (<i>p</i> &lt; 0.01), HAMA scores&#xa0;from 19.68&#xa0;to&#xa0;15.44 (<i>p</i> &lt; 0.05), and QIDS scores&#xa0;from 13.52to&#xa0;9.68 (<i>p</i> &lt; 0.001). Eleven participants (44.0%) met improvement criteria and seven (28.0%) achieved response. Cognitive assessments indicated improvements in memory and executive function, and changes in reward-related brain activity correlated positively with symptom reduction. Adverse events were mild, mainly transient scalp discomfort. These findings provide preliminary evidence supporting the efficacy and safety of tTIS for alleviating depressive symptoms and cognitive impairments in BD-D.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Transcranial temporal interference stimulation for treating bipolar disorder with depressive episodes: a feasibility Study

  • 期刊论文

  • 发表日期：

    2025年10月2日

查看全文
  • Hetong Zhou,
  • Minmin Wang,
  • Shuangyu Qi,
  • Qianfeng Chen,
  • Jianbo Lai,
  • Zhengping Wu,
  • Ruobing Liu,
  • Liang Wang,
  • Hui Zhou,
  • Shaomin Zhang,
  • Shaohua Hu

摘要

Bipolar depression (BD-D) is a significant clinical challenge associated with high disease burden. Transcranial temporal interference stimulation (tTIS), a novel and noninvasive approach for targeting deep brain structures, was investigated for its efficacy and safety in BD-D patients in this trial. Thirty-six patients were recruited for a single-arm, open-label trial, and 25 completed the 5-day intervention consisting of 10 tTIS sessions targeting the left nucleus accumbens. Each session lasted 20 min, with a maximum current intensity of 2 mA and an envelope stimulation frequency of 40 Hz. Significant symptom reductions were observed following treatment, with mean HAMD-17 scores decreasing from 23.36 to 16.16 (p < 0.0001), MADRS scores from 39.12 to 31.28 (p < 0.01), HAMA scores from 19.68 to 15.44 (p < 0.05), and QIDS scores from 13.52to 9.68 (p < 0.001). Eleven participants (44.0%) met improvement criteria and seven (28.0%) achieved response. Cognitive assessments indicated improvements in memory and executive function, and changes in reward-related brain activity correlated positively with symptom reduction. Adverse events were mild, mainly transient scalp discomfort. These findings provide preliminary evidence supporting the efficacy and safety of tTIS for alleviating depressive symptoms and cognitive impairments in BD-D.